Journals / Journal of Clinical and Analytical Medicine / 2012 / Cilt: 3 - Sayı: 1

Malign plevral mezotelyoma: Klinik, patolojik ve radyolojik bulgular

Malignant mesothelioma: Clinical, pathological and radiological findings

Pages
51–55
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A multimodality approach comprises the present MPM treatment, but total cure cannot be provided.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Malignant pleural mesothelioma is a tumor of locally invasive character and of fatal course, frequently arising following asbest exposure.
📊
Key Findings & Data:In the present study we attempted to retrospectively evaluate the clinical, pathological, and radiological findings of 27 cases diagnosed with MPM.
💡
Conclusion & Impact:A multimodality approach comprises the present MPM treatment, but total cure cannot be provided.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Malignant pleural mesothelioma is a tumor of locally invasive character and of fatal course, frequently arising following asbest exposure. In the present study we attempted to retrospectively evaluate the clinical, pathological, and radiological findings of 27 cases diagnosed with MPM. Material and Method: 27 cases diagnosed with MPM in our medical facility have been included into the study, 14 females, and 13 males. Of the cases, 4 have been diagnosed based on transthoracic pleural biopsy, and 23 – using surgical methods (VYTC, thoracotomy). Result: Radiological evaluation revealed pleural thickening in 23 (85.2%), pleural effusion in 20 (74.1%), volume loss in 15 (55.6%), pleural nodulation in 14 (51.9%), mediastinal shift in 4 (14.8%), pneumothorax in 1 (3.7%), and hydropneumothorax in 1 (3.7%) of the cases, respectively. Histopathological examination failed to reveal any typing in 17 (63%) of the cases. On the other hand, 5 (18.5%) of the remainder cases were of the epitheloid type, 4 (14.8%) were of the sarcomatoid type, and 1 (3.7%) was of the biphasic MPM type. Mean survival rate of the 3 (11.1%) Stage I cases was 1449 days, of the 6 (22.2%) Stage II cases was 480 days, of the 18 (66.7%) Stage III cases was 214 days. We had no Stage IV cases at the time of diagnosis. A statistically significant difference has been established between the Stage and the mean survival rate of the cases. Discussion: In diagnosing MPM, proper histopathological exam followed by proper radiological staging should be carried out. A multimodality approach comprises the present MPM treatment, but total cure cannot be provided.

Özet

Amaç: Malign plevral mezotelyoma (MPM), agresif lokal invazif karakteri olan fatal seyirli bir tümör olup, sıklıkla asbest teması sonucu oluşur. Bu çalışmada MPM tanısı alan 27 olgunun klinik, patolojik ve radyolojik bulgularını retrospektif olarak literatür eşliğinde irdelemek istedik. Gereç ve Yöntem: Merkezimizde MPM tanısı alan 27 olgu, 14’ü kadın, 13’ü erkek çalışmaya alındı. Olguların 4’üne transtorasik plevra biyopsisi ile, 23’üne ise cerrahi yöntemler (VYTC, torakotomi) ile tanı konuldu. Bulgular: Radyolojik değerlendirmede sırası ile 23’ünde (%85.2) plevral kalınlaşma, 20’sinde (%74.1) plevral effüzyon, 15’inde (%55.6) hacim kaybı, 14’ünde (%51.9) plevral nodülasyon, 4’ünde (%14.8) mediyastinal shift, birinde (%3.7) pnömotoraks, birinde ise (% 3.7) hidropnömotoraks tespit edildi. Histopatolojik incelemede 17 (%63) olgunun tiplendirmesi yapılamadı. On olgunun ise 5’i (%18.5) epiteloid tip, 4’ü (%14.8) sarkomatoid tip ve 1’i (%3.7) bifazik tip MPM olarak rapor edildi. Evre I’de 3 (%11.1) olgunun ortalama yaşam süresi 1449 gün, evre II’de 6 (%22.2) olgunun ortalama yaşam süresi 480 gün, evre III’de 18 (%66.7) olgunun ortalama yaşam süresi 214 gün olarak tespit edildi. Tanı esnasında evre IV olgumuz olmadı. Olguların evresi ile ortalama yaşam süreleri arasında istatistiksel olarak anlamlı fark (p = 0.007) saptandı. Sonuç: MPM tanısı için uygun histopatolojik inceleme ve ardından uygun radyolojik evrelendirme yapılmalıdır. MPM tedavisinde günümüzde multimodaliter yaklaşım öne çıkmakla birlikte hastalığa ilişkin tam kür sağlanamamaktadır.

🔖

Cite This Article

KATRANCIOĞLU, Ö., LAKADAMYALI, H., DÖNGEL, İ., YILDIRIM, Y., SAPMAZ, F. (2022). Malign plevral mezotelyoma: Klinik, patolojik ve radyolojik bulgular. Journal of Clinical and Analytical Medicine, Cilt: 3 - Sayı: 1, 51–55. https://ajindex.com/articles/561448

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. De Bree E, Ruth SV, Bass P, Rutgers EJ, Zondwijk NV, Witkamp AJ, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastaes of thymoma. Chest 2002; 121: 480- 7
  2. Pass HI, Robinson BW, Testa JR, Carbone M. Emerging translatinal therapies for mesothelioma. Chest 1999; 116: 455-60
  3. Boutin C. Activity of intrapleural recombinant gamma - interferon in malignant mesothelioma. Cancer 1991; 67: 2033
  4. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999;180(2):150- 7
  5. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Corson JM, Antman KH. Node has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin Oncol 1993; 11: 1172- 8
  6. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55
  7. Tuğ T, Tuğ E. Asbest maruziyeti ve malign mezotelyoma’da etiyopatogenez ve epidemiyolojik özellikler; Tümör süpresör gen ilişkileri. Turkiye Klinikleri J Med Sci 2005; 25:436- 44
  8. Karakoca Y, Emri S, Bagci T, Demir A, Erdem Y, Baris E, et al. Enviromentallyinduced malignant pleural mesothelioma and HLA distribution in Turkey. Int J Tuberc Lung Dis 1998; 2:1017- 22
  9. De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem 2002; 84:455-9. 10.http://www.mta.gov.tr/v1.0/turkiye_maden/maden_potansiyel_2010/sivas_ madenler.pdf 11. Başıbüyük Z, Yalçın Y, Bozkaya Ö. Sivas Bölgesi ofiyolitleri ile ilişkili, asbest yataklarının minerolojisi
  10. Ulusal Kil Sempozyumu, Bildiriler Kitabı, s. 11- 26
  11. Köksal D, Beder S. Malign plevral mezotelyoma tedavisi. Tüberküloz ve Toraks Dergisi 2003; 51(3):310-19
  12. Sahin AA, Cöplü L, Selçuk ZT, Eryilmaz M, Emri S, Akhan O, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. Am J Roentgenol 1993; 161(3):533- 7
  13. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211- 8
  14. Davies CW, Traill ZC, Gleeson FV, Davies RJ. Intrapleural streptokinase in the management of malignant multiloculated pleural